Galvanize Therapeutics Gains FDA Approval for Aliya EX Generator to Enhance Soft Tissue Surgical Ablation

Galvanize Therapeutics Gains FDA Clearance for Aliya EX Generator

Galvanize Therapeutics, Inc. has made headlines with its recent achievement of receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for the Aliya® EX Generator. This next-generation device is a further development in the company’s portfolio of pulsed electric field (PEF) therapies, specifically aimed at enhancing surgical ablation of soft tissues.

The Aliya EX Generator is designed to enable healthcare providers to treat a broader range of lesion sizes effectively. Compared to its predecessor, this innovative system boasts the capacity to produce an ablation diameter that is up to twice as large, leading to an impressive sevenfold increase in the volume of tissue that can be treated. Notably, it retains the fundamental characteristics of Aliya PEF energy, which include predictable, non-thermal ablation and a beneficial safety profile.

In addition to these improvements, the Aliya EX Generator is compatible with current biopsy workflows and standard oncological therapies. An intriguing aspect of the device is its potential for immune system activation, which positions it as a valuable complement to other treatment modalities.

Dr. Michael Pritchett, Director of the Chest Center of the Carolinas, emphasized the transformative nature of Aliya PEF technologies in patient care. He noted that the Aliya EX’s capability to adapt to the size and shape of tissue encourages the exploration of treatment options for patients who otherwise have limited alternatives due to their circumstances. This flexibility opens the door to addressing cases previously deemed ineligible for such interventions, thereby broadening the scope of what can be achieved in longitudinal cancer care and multidisciplinary treatment approach planning.

Aliya PEF technology functions by delivering short, high-voltage electrical pulses to targeted tissues, facilitating a non-thermal form of regulated cell death. Initial preclinical and clinical investigations have indicated that this method might promote the release of antigens and stimulate immune responses while preserving the architecture of surrounding tissues.

The importance of the Aliya EX Generator cannot be overstated, according to Doug Godshall, the CEO of Galvanize Therapeutics. He commented that this advancement significantly expands interventional options available to physicians and patients, all while maintaining procedural consistency and the biological mechanisms that characterize their platform.

Following this crucial clearance, the Aliya EX Generator will proceed with a limited commercial rollout within the United States, reflecting the company's commitment to addressing unmet medical needs in cancer treatment and chronic lung diseases.

About Aliya® PEF Energy

The Aliya EX System is meticulously crafted for the surgical ablation of soft tissues by inducing non-thermal regulated cell death through targeted electrical energy. While early data suggest that Aliya PEF could activate the immune system, the definitive effectiveness of this system in inducing a beneficial immune response remains to be conclusively established.

About Galvanize Therapeutics

Based in Redwood City, California, Galvanize Therapeutics is on a mission to become a worldwide leader in medical technology innovations designed to harness biological processes for treating various patient populations. Their work encompasses addressing soft tissue lesions as well as chronic bronchitis through the development and commercialization of the Aliya® PEF energy platform.

For further details about their initiatives, visit www.galvanizetx.com.